The RNA receptor RIG-I binding synthetic oligodeoxynucleotide promotes pneumonia survival.

Area of Science:

• Immunology
• Infectious Diseases
• Respiratory Medicine

Background:

• Pneumonia poses a global health threat, necessitating new treatments.
• Lung epithelial cells are key in pathogen defense and sensing.
• Previous studies showed synthetic CpG oligodeoxynucleotides (ODN) protect against pneumonia.

Purpose of the Study:

• To investigate the mechanism of ODN-induced pneumonia protection.
• To identify alternative receptors for ODN beyond TLR9.
• To explore the role of RIG-I in ODN-mediated immune responses.

Main Methods:

• Utilized mice deficient in Toll-like receptor 9 (TLR9).
• Employed mass spectrometry to identify ODN-binding proteins.
• Investigated RIG-I (retinoic acid-inducible gene I) activation and downstream signaling via MAVS (Mitochondrial Antiviral Signaling protein).

Main Results:

• Mice lacking TLR9 still showed partial protection from ODN treatment.
• Mass spectrometry identified RIG-I as an ODN-binding protein.
• RIG-I activation by ODN led to MAVS-dependent protective signaling.
• Therapeutic RIG-I activation with ODN improved survival in both viral and bacterial pneumonia models.
• Maximal protection required activation of both TLR9/MyD88 and RIG-I/MAVS pathways.

Conclusions:

• RIG-I acts as a novel pattern recognition receptor for DNA-like ODN molecules.
• Dual activation of TLR9 and RIG-I pathways is crucial for optimal ODN-induced pneumonia protection.
• Therapeutic targeting of RIG-I offers a promising strategy against lethal pneumonias.